IFNB1 and airway hyperresponsiveness: IFN-β treatment, used by either oral[18] or parenteral[17] via in mice, have shown to produce an inhibition of antigen-induced bronchial inflammation and airway hyperresponsiveness [17,18] probably influenced by the inhibition of Th-2 airway eosinophilia by the suppressive effect on eosinopoiesis [57].